Biogen Idec Says Long-Lasting Hemophilia Drug Meets Safety Goals

Biogen Idec (BIIB) and Swedish Orphan Biovitrum said a potential hemophilia B treatment has metsafety goals in an early-stage study.

The study involved 14 previously treated patients, and the data showed that the drug, rFIXFc, was well tolerated and demonstrated an approximately three-fold increase in half-life, compared to previous data for existing therapies. That would give provide prolonged protection with a single dose.

The study was presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010. Based on this study, the companies said they'll conduct a global registrational trial of the safety and effectiveness of the drug with 75 patients.

Hemophilia is a rare, inherited disorder in which patients have an impaired ability for blood clotting, leading to excessive bleeding. Current treatments require intravenous injections twice a week. This drug, the companies hope, would reduce the injections to once a week.

Read Full Story

Markets

DJIA 24,575.62 171.14 0.70%
NASDAQ 7,025.77 5.41 0.08%
NIKKEI 225 20,506.81 -86.91 -0.42%
DAX 11,071.54 -18.57 -0.17%
HANG SENG 27,052.04 43.84 0.16%
USD (per EUR) 1.14 0.00 0.01%
JPY (per USD) 109.51 0.02 0.02%
GBP (per USD) 1.31 0.00 -0.04%
USD (per CHF) 0.99 0.00 -0.07%